| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.
|
Immunity
|
2005
|
3.14
|
|
2
|
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
|
Blood
|
2010
|
2.41
|
|
3
|
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
|
Cancer Cell
|
2010
|
2.37
|
|
4
|
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
|
Blood
|
2007
|
2.15
|
|
5
|
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
|
EMBO J
|
2007
|
2.08
|
|
6
|
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
|
Cancer
|
2014
|
1.68
|
|
7
|
IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice.
|
Blood
|
2004
|
1.52
|
|
8
|
Versatility of PRMT5-induced methylation in growth control and development.
|
Trends Biochem Sci
|
2011
|
1.44
|
|
9
|
Novel targeted therapies for mantle cell lymphoma.
|
Oncotarget
|
2012
|
1.27
|
|
10
|
EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-associated disease.
|
Virology
|
2006
|
1.25
|
|
11
|
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
|
Clin Cancer Res
|
2010
|
1.21
|
|
12
|
The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene.
|
Mol Cell Biol
|
2005
|
1.20
|
|
13
|
Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer.
|
Brain Behav Immun
|
2005
|
1.19
|
|
14
|
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
|
J Clin Oncol
|
2009
|
1.13
|
|
15
|
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
|
PLoS One
|
2010
|
1.11
|
|
16
|
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
|
Blood
|
2011
|
1.10
|
|
17
|
Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
|
Clin Cancer Res
|
2012
|
1.04
|
|
18
|
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
|
Clin Cancer Res
|
2004
|
1.04
|
|
19
|
Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
|
Cancer Res
|
2003
|
1.03
|
|
20
|
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
|
J Biol Chem
|
2013
|
1.01
|
|
21
|
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
|
Cancer Res
|
2014
|
1.00
|
|
22
|
Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation.
|
J Cutan Pathol
|
2005
|
0.97
|
|
23
|
Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
|
Leuk Res
|
2007
|
0.97
|
|
24
|
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.
|
Blood
|
2005
|
0.97
|
|
25
|
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
|
Blood
|
2011
|
0.95
|
|
26
|
PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).
|
PLoS One
|
2013
|
0.92
|
|
27
|
Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.
|
Am J Hematol
|
2010
|
0.91
|
|
28
|
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
|
MAbs
|
2010
|
0.91
|
|
29
|
Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy.
|
Clin Adv Hematol Oncol
|
2009
|
0.91
|
|
30
|
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
|
J Natl Cancer Inst
|
2004
|
0.91
|
|
31
|
Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues.
|
Inorg Chem
|
2011
|
0.91
|
|
32
|
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
|
Br J Haematol
|
2014
|
0.90
|
|
33
|
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.
|
Blood
|
2005
|
0.90
|
|
34
|
Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
|
Transplantation
|
2015
|
0.85
|
|
35
|
Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male.
|
Head Neck Pathol
|
2012
|
0.82
|
|
36
|
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?
|
Autophagy
|
2012
|
0.82
|
|
37
|
Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration.
|
Blood
|
2002
|
0.82
|
|
38
|
The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods.
|
Methods
|
2010
|
0.81
|
|
39
|
The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
|
J Cutan Pathol
|
2005
|
0.78
|
|
40
|
Recent developments in the biology and therapy of T-cell and natural killer-cell lymphomas.
|
Curr Opin Oncol
|
2003
|
0.76
|
|
41
|
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
42
|
Correction: PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.
|
J Immunol
|
2017
|
0.75
|